Dongyang Guang Pharma: 2025 Growth of 228.57% to Approximately 270 Million Yuan, Core Products Experience Significant Increase in Market Demand

LightningPacketLoss · 2026-03-16T18:26:23+00:00

Dongyang Guangyao Pharmaceutical is expected to achieve net profit attributable to shareholders of 270 million yuan in 2025, turning from losses to profitability, representing a significant increase of 228.57% compared to the net loss of 210 million yuan in the previous year. The performance growth is mainly due to the high incidence of flu epidemics, with demand for the core drug oseltamivir phosphate showing a significant rise.

LightningPacketLoss

2026-03-16 18:26:23

Abstract generation in progress

Recently, Dongyang Sunshine Pharmaceutical announced that, based on the group’s unaudited management accounts and preliminary estimates by management, it is expected to achieve a net profit attributable to the parent company of approximately RMB 270 million for the year ending December 31, 2025. This represents a turnaround from a net loss of about RMB 210 million in the same period last year, with a significant increase of approximately 228.57% year-on-year.

The performance forecast growth is mainly due to a notable increase in influenza cases in the second half of 2025. The company’s core product, Oseltamivir Phosphate, is the preferred medication for flu prevention and treatment, leading to a substantial rise in market demand.

(Dongyang Sunshine Pharmaceutical Announcement)

(Edited by: Yang Yan, Lin Chen)

Keywords: Healthcare

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes